已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract LB031: SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles

旁观者效应 曲妥珠单抗 医学 癌症研究 药理学 乳腺癌 化学 癌症 内科学 免疫学
作者
Ting Zhang,Lingfeng You,Jianyan Xu,Junzhao Yin,Bolei Qu,Yuchang Mao,Beibei Fu,Dan Cao,Linda Zhao,Jun Feng,Min Hu,Feng He
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (8_Supplement): LB031-LB031 被引量:6
标识
DOI:10.1158/1538-7445.am2023-lb031
摘要

Abstract Current clinical HER2-targeting ADCs, especially T-DXd, have shown strong efficacy in HER2-expressing/mutant cancers, however, with adverse events such as hematologic toxicities and interstitial lung disease (ILD)/pneumonitis. Here we presented a potential best-in-class HER2-directed ADC, SHR-A1811, which was composed of trastuzumab, a stable and cleavable linker, and a novel topoisomerase I inhibitor payload (SHR9265). SHR9265 was a delicately selected exatecan derivative with a better liposolubility and cellular permeability: SHR9265 had a higher AlogP value than SHR7971, synthesized using published DXd structure (3.67 vs. 2.72). Consistently, SHR9265 showed ~5 times higher membrane permeability (PAMPA model) at pH5 and pH7.4. Cell killing activity of SHR9265 was ~3 times more potent than SHR7971. SHR-A1811 had a drug-to-antibody ratio (DAR) of 5.7, and showed HER2-dependent growth inhibition against various breast cancer and gastric cancer cell lines. In the bystander killing system, SHR-A1811 was able to kill both SK-BR-3 (HER2+) and MDA-MB-468 (HER2-) cells when co-cultured, with the IC50 on MDA-MB-468 of 0.28 nM. The in vitro efficacy of SHR-A1811 was comparable with anti-Her2-SHR9265 (DAR 7.5) and ADC1 (synthesized using T-DXd structure), and stronger than anti-Her2-SHR9265 (DAR 3.5). In SK-BR-3 (HER2 high), JIMT-1 (HER2 moderate) and capan-1 (HER2 low) xenograft models, SHR-A1811 treatment resulted in a dramatic and sustained inhibition of tumor growth. A significantly stronger antitumor activity was observed for SHR-A1811 than ADC1 under the same dosages. Moreover, SHR-A1811 showed good stability and improved safety profiles, presumably due to the proper steric hindrance which was purposely designed on the payload (SHR9265). Less than 2% of payload release was observed in human plasma after a 21-day incubation. The HNSTD of SHR-A1811 in cynomolgus monkeys was 40mpk with thymus as the main target organ. No death and lung lesions were observed at dose levels up to 70mpk for 42 days, while ADC1 led to one male cynomolgus monkey death on day 10 at 70mpk with multiple lung damages. These findings were consistent with safety profiles observed in a multi-center, dose-escalation phase I clinical trial (NCT0444620). Patients with different solid tumor types received initial intravenous doses of SHR-A1811 from 1 to 8.0 mg/kg. Only trace amount of free toxin was detected. The Cmax of payload was 3.85 ng/ml at 8mg/kg of SHR-A1811. The incidence of G2 ILD was < 2.5% and the treatment discontinuation rate was 5.1% across doses. In summary, with a highly permeable payload, optimized DAR, great potency and better clinical safety profiles, SHR-A1811 has demonstrated the best-in-class potential. Currently SHR-A1811 has entered phase II and phase III clinical studies for breast cancer, gastric cancer, colorectal cancer, and NSCLC (NCT05424835, NCT05482568, NCT04818333, NCT05349409). Citation Format: Ting Zhang, Lingfeng You, Jianyan Xu, Junzhao Yin, Bolei Qu, Yuchang Mao, Beibei Fu, Dan Cao, Linda Zhao, Jun Feng, Min Hu, Feng He. SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB031.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI5应助芯之痕采纳,获得10
刚刚
刚刚
Sugar完成签到,获得积分20
1秒前
单身的老太完成签到,获得积分10
1秒前
派大星发布了新的文献求助10
2秒前
5秒前
激昂的沛柔完成签到,获得积分10
5秒前
李世航发布了新的文献求助30
5秒前
7秒前
硫化铅完成签到,获得积分10
7秒前
Luchy完成签到 ,获得积分10
8秒前
量子星尘发布了新的文献求助10
8秒前
10秒前
CipherSage应助鲁西西采纳,获得10
10秒前
10秒前
zhantianao发布了新的文献求助10
12秒前
壮观的谷冬完成签到 ,获得积分0
12秒前
13秒前
znlion发布了新的文献求助10
15秒前
落叶捎来讯息完成签到 ,获得积分10
15秒前
Dz1990m发布了新的文献求助10
18秒前
myg123完成签到 ,获得积分10
19秒前
zhantianao完成签到,获得积分10
19秒前
1234567完成签到,获得积分20
20秒前
缓慢的灵枫完成签到 ,获得积分10
21秒前
天空完成签到,获得积分10
21秒前
老马哥完成签到 ,获得积分0
24秒前
迷人的天抒应助焦立超采纳,获得10
28秒前
薏米人儿完成签到 ,获得积分10
31秒前
Marciu33应助1234567采纳,获得20
32秒前
含糊的非笑完成签到,获得积分10
32秒前
znlion完成签到,获得积分10
34秒前
36秒前
36秒前
36秒前
HUO完成签到 ,获得积分10
38秒前
38秒前
Rondab应助科研通管家采纳,获得10
40秒前
Rondab应助科研通管家采纳,获得10
40秒前
40秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976572
求助须知:如何正确求助?哪些是违规求助? 3520659
关于积分的说明 11204365
捐赠科研通 3257284
什么是DOI,文献DOI怎么找? 1798667
邀请新用户注册赠送积分活动 877835
科研通“疑难数据库(出版商)”最低求助积分说明 806577